ICU Medical (ICUI) Getting Somewhat Positive Press Coverage, Study Shows

Headlines about ICU Medical (NASDAQ:ICUI) have been trending somewhat positive on Tuesday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ICU Medical earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 44.4757931978913 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Shares of ICUI stock traded down $4.70 during trading hours on Tuesday, hitting $265.65. The company’s stock had a trading volume of 2,703 shares, compared to its average volume of 126,587. The company has a market capitalization of $5.37 billion, a P/E ratio of 48.98 and a beta of 0.36. ICU Medical has a 12-month low of $265.65 and a 12-month high of $270.35.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Wednesday, May 9th. The medical instruments supplier reported $2.26 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.84 by $0.42. ICU Medical had a net margin of 1.25% and a return on equity of 9.55%. The firm had revenue of $372.00 million for the quarter, compared to the consensus estimate of $346.28 million. During the same period in the prior year, the firm posted $1.68 earnings per share. The firm’s quarterly revenue was up 50.2% compared to the same quarter last year. equities analysts forecast that ICU Medical will post 6.29 earnings per share for the current year.

Several research firms have recently commented on ICUI. TheStreet downgraded shares of ICU Medical from an “a” rating to a “c+” rating in a report on Wednesday, May 9th. Zacks Investment Research downgraded shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 3rd. Finally, BidaskClub raised shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 28th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $266.00.

In related news, Director George A. Lopez sold 7,640 shares of the stock in a transaction on Wednesday, March 21st. The shares were sold at an average price of $253.83, for a total transaction of $1,939,261.20. Following the sale, the director now directly owns 526,574 shares of the company’s stock, valued at $133,660,278.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joseph R. Saucedo sold 1,566 shares of the stock in a transaction on Monday, May 14th. The stock was sold at an average price of $269.02, for a total transaction of $421,285.32. The disclosure for this sale can be found here. Insiders have sold 100,680 shares of company stock worth $25,555,077 over the last three months. 12.50% of the stock is currently owned by insiders.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Insider Buying and Selling by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply